Activity Overview
This online, on-demand virtual symposium brings together renowned experts in metastatic triple-negative breast cancer (TNBC). In this educational program, these experts discuss PD-L1 testing and CPS scoring in metastatic TNBC, including assay selection, interpretation of borderline and discordant results, and access and disparities in biomarker-driven care. Case discussions, an overview of testing strategies, and panel discussions with faculty help learners interpret PD-L1 testing results using CPS scoring and appropriate assay selection to assess patient eligibility for immunotherapy approaches.
This educational activity is an archive of the live symposium held on August 10, 2026.
Target Audience
This educational activity is directed toward medical oncologists, advanced practice providers, nurses, pathologists, and other health care providers involved in the management of metastatic triple-negative breast cancer (TNBC). Both the live Project ECHO tele-mentoring sessions and the archived, enduring online activities are directed toward a global audience of oncology clinicians, with open-access availability via www.gotoper.com, to practitioners outside the United States.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Interpret PD-L1 testing results using CPS scoring and appropriate assay selection to assess patient eligibility for immunotherapy approaches in metastatic TNBC
- Enhance patient communication strategies to ensure alignment on treatment expectations and goals
Tiffany A. Traina, MD, FASCO
Associate Attending Physician
Vice Chair, Oncology; Department of Medicine
Section Head, Triple Negative Breast Cancer Clinical Research Program
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine, Weill Cornell Medicine
New York, NY
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Aktis Oncology, AstraZeneca, BioNTech SE, Daiichi Sankyo, Ellipses Pharma, Exact Sciences, Genentech/Roche, Gilead Sciences, Merck, Pfizer, Stemline Therapeutics, TerSera Therapeutics; Grant/Research Funding (to institution): Astellas Pharma, AstraZeneca, BioNTech SE, Daiichi Sankyo, Genentech/Roche, Pfizer
Nour Abuhadra, MD
Assistant Professor
Co-Director, Rare Breast Cancer Program, Department of Medicine
Co–Section Head, Triple Negative Breast Cancer Clinical Research Program, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Nour Abuhadra, MD, has no relevant financial relationships with ineligible companies.
Francesca Gany, MD, MS
Chief of Service, Immigrant Health and Cancer Disparities
Nicholls-Biondi Chair for Community Health Equity
Co-Director, Geoffrey Canada Center for Translational Cancer Disparities Research
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Francesca Gany, MD, MS, has no relevant financial relationships with ineligible companies.
Hannah Y. Wen, MD, PhD
Director, Breast Pathology Fellowship
Associate Team Leader, Breast Pathology Team
Attending Pathologist
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca; Speakers Bureau: Daiichi Sankyo
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.
This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
